Published 2 days ago • loading... • Updated 12 hours ago

Quantum BioPharma & MGH Launch PET Imaging Study for MS Demyelination

Summary

Quantum BioPharma Ltd. a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that on March 31, 2025 it has entered into a joint clinical study with Massachusetts General Hospital (MGH) scientists to validate a novel positron emission tomography (PET) imaging technique to monitor myelin integrity and demyelination in people with multiple sclerosis (MS).

9 Articles

All

Left

Center

Right

Inside Halton

+7 Reposted by 7 other sources

Lean Left

Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis

TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that on March 31,…

2 days ago·Halton Hills, Canada

Read Full Article

ScienceDirect

Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis

Multiple sclerosis (MS), an inflammatory demyelinating disease, is a major cause of neurological disability in young adults in the developed world. Al…

12 hours ago·Amsterdam, Netherlands

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year